×
QQQ   286.96 (+1.71%)
AAPL   141.56 (+1.89%)
MSFT   262.85 (+1.26%)
META   168.19 (+5.10%)
GOOGL   2,265.26 (+4.16%)
AMZN   113.50 (+3.60%)
TSLA   699.20 (+2.55%)
NVDA   149.64 (+3.04%)
NIO   22.18 (+3.84%)
BABA   120.13 (+3.56%)
AMD   75.20 (+2.08%)
MU   56.73 (+5.74%)
CGC   2.71 (-3.56%)
T   21.17 (-0.66%)
GE   62.03 (-2.38%)
F   11.20 (-1.06%)
DIS   97.18 (+1.08%)
AMC   12.78 (-5.54%)
PFE   51.64 (-1.28%)
PYPL   74.40 (+4.20%)
NFLX   185.88 (+3.30%)
QQQ   286.96 (+1.71%)
AAPL   141.56 (+1.89%)
MSFT   262.85 (+1.26%)
META   168.19 (+5.10%)
GOOGL   2,265.26 (+4.16%)
AMZN   113.50 (+3.60%)
TSLA   699.20 (+2.55%)
NVDA   149.64 (+3.04%)
NIO   22.18 (+3.84%)
BABA   120.13 (+3.56%)
AMD   75.20 (+2.08%)
MU   56.73 (+5.74%)
CGC   2.71 (-3.56%)
T   21.17 (-0.66%)
GE   62.03 (-2.38%)
F   11.20 (-1.06%)
DIS   97.18 (+1.08%)
AMC   12.78 (-5.54%)
PFE   51.64 (-1.28%)
PYPL   74.40 (+4.20%)
NFLX   185.88 (+3.30%)
QQQ   286.96 (+1.71%)
AAPL   141.56 (+1.89%)
MSFT   262.85 (+1.26%)
META   168.19 (+5.10%)
GOOGL   2,265.26 (+4.16%)
AMZN   113.50 (+3.60%)
TSLA   699.20 (+2.55%)
NVDA   149.64 (+3.04%)
NIO   22.18 (+3.84%)
BABA   120.13 (+3.56%)
AMD   75.20 (+2.08%)
MU   56.73 (+5.74%)
CGC   2.71 (-3.56%)
T   21.17 (-0.66%)
GE   62.03 (-2.38%)
F   11.20 (-1.06%)
DIS   97.18 (+1.08%)
AMC   12.78 (-5.54%)
PFE   51.64 (-1.28%)
PYPL   74.40 (+4.20%)
NFLX   185.88 (+3.30%)
QQQ   286.96 (+1.71%)
AAPL   141.56 (+1.89%)
MSFT   262.85 (+1.26%)
META   168.19 (+5.10%)
GOOGL   2,265.26 (+4.16%)
AMZN   113.50 (+3.60%)
TSLA   699.20 (+2.55%)
NVDA   149.64 (+3.04%)
NIO   22.18 (+3.84%)
BABA   120.13 (+3.56%)
AMD   75.20 (+2.08%)
MU   56.73 (+5.74%)
CGC   2.71 (-3.56%)
T   21.17 (-0.66%)
GE   62.03 (-2.38%)
F   11.20 (-1.06%)
DIS   97.18 (+1.08%)
AMC   12.78 (-5.54%)
PFE   51.64 (-1.28%)
PYPL   74.40 (+4.20%)
NFLX   185.88 (+3.30%)
OTCMKTS:QBIO

Q BioMed Stock Forecast, Price & News

$0.05
0.00 (0.00%)
(As of 07/5/2022 12:00 AM ET)
Add
Compare
Today's Range
$0.05
$0.05
50-Day Range
$0.05
$0.31
52-Week Range
$0.04
$0.92
Volume
266,380 shs
Average Volume
185,093 shs
Market Capitalization
$2.06 million
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
N/A

Q BioMed MarketRank™ Forecast

Analyst Rating
N/A
Upside/​Downside
N/A
Short Interest
Healthy
0.06% of Shares Sold Short
Dividend Strength
N/A
Sustainability
N/A
News Sentiment
N/A
Insider Trading
N/A
Proj. Earnings Growth
N/A

Overall MarketRank

MarketRank is calculated as 30% analysis score, 20% valuation score, 10% short interest score, 10% dividend score, 10% sustainability score, 10% news and social score, and 10% insider trading score.

0.22 out of 5 stars

30 days | 90 days | 365 days | Advanced Chart

Receive QBIO Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Q BioMed and its competitors with MarketBeat's FREE daily newsletter.

Q BioMed logo

About Q BioMed (OTCMKTS:QBIO) Stock

Q BioMed Inc., a biomedical acceleration and development company, focuses on licensing, acquiring, and providing resources to life sciences and healthcare companies. The company offers Strontium Chloride SR89 and Metastron, a radiopharmaceutical therapeutic for the treatment of metastatic bone cancer pain. It is also developing Man-01, a pre-clinical lead candidate for the treatment of primary open angle glaucoma; QBM-001 for rare pediatric non-verbal autism spectrum disorder; and Uttroside-B for liver cancer. Q BioMed Inc. has a partnership with Mannin Research Inc. for the development of therapeutics to treat acute respiratory distress syndrome, glaucoma, kidney diseases, and others. The company was formerly known as ISMO Tech Solutions, Inc. and changed its name to Q BioMed Inc. in July 2015. Q BioMed Inc. was incorporated in 2013 and is based in New York, New York.

QBIO Stock News Headlines

Q BioMed Inc. (OTCMKTS:QBIO) Short Interest Down 48.9% in May
Q BioMed Inc (QBIO)
Q BioMed outlines strategic direction and goals for 2022
Q BioMed Outlines Strategic Direction for 2022
Q BioMed Inc. Provides Shareholder Update
See More Headlines

Industry, Sector and Symbol

Industry
Pharmaceutical preparations
Sub-Industry
N/A
Sector
Medical
Current Symbol
OTCMKTS:QBIO
Previous Symbol
NASDAQ:QBIO
Fax
N/A
Employees
3
Year Founded
N/A

Company Calendar

Last Earnings
4/14/2022
Today
7/05/2022
Fiscal Year End
11/30/2022

Profitability

Net Income
$-8,240,000.00
Net Margins
-2,971.96%
Pretax Margin
-2,972.32%

Debt

Sales & Book Value

Annual Sales
$200,000.00
Book Value
($0.37) per share

Miscellaneous

Free Float
N/A
Market Cap
$2.06 million
Optionable
Not Optionable
Beta
1.74














Q BioMed Frequently Asked Questions

How has Q BioMed's stock price performed in 2022?

Q BioMed's stock was trading at $0.43 at the start of the year. Since then, QBIO stock has decreased by 88.4% and is now trading at $0.05.
View the best growth stocks for 2022 here
.

Are investors shorting Q BioMed?

Q BioMed saw a decline in short interest in the month of May. As of May 31st, there was short interest totaling 25,300 shares, a decline of 48.9% from the May 15th total of 49,500 shares. Based on an average trading volume of 744,100 shares, the days-to-cover ratio is currently 0.0 days.
View Q BioMed's Short Interest
.

How were Q BioMed's earnings last quarter?

Q BioMed Inc. (OTCMKTS:QBIO) released its quarterly earnings data on Thursday, April, 14th. The company reported ($0.08) earnings per share for the quarter. The business had revenue of $0.08 million for the quarter.
View Q BioMed's earnings history
.

Who are Q BioMed's key executives?

Q BioMed's management team includes the following people:
  • Mr. Denis D. Corin, Chairman, CEO & Pres (Age 49, Pay $300k)
  • Mr. William S. Rosenstadt, Chief Legal Officer, Gen. Counsel & Director (Age 54, Pay $300k)
  • Mr. David Laskow-Pooley, VP of Product Devel. (Age 68)
  • Mr. Robert Derham, VP of Orphan Products
  • Mr. Ari Jatwes, Bus. Devel. Analyst
  • Dr. Amy Ripka, Medicinal Chemistry Advisor

What other stocks do shareholders of Q BioMed own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Q BioMed investors own include NVIDIA (NVDA), Micron Technology (MU), Washington Trust Bancorp (WASH), Nokia Oyj (NOK), (CGC), Cisco Systems (CSCO), Inovio Pharmaceuticals (INO), Intel (INTC), OPKO Health (OPK) and AT&T (T).

What is Q BioMed's stock symbol?

Q BioMed trades on the OTCMKTS under the ticker symbol "QBIO."

How do I buy shares of Q BioMed?

Shares of QBIO can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

What is Q BioMed's stock price today?

One share of QBIO stock can currently be purchased for approximately $0.05.

How much money does Q BioMed make?

Q BioMed (OTCMKTS:QBIO) has a market capitalization of $2.06 million and generates $200,000.00 in revenue each year. The company earns $-8,240,000.00 in net income (profit) each year or ($0.31) on an earnings per share basis.

How many employees does Q BioMed have?

Q BioMed employs 3 workers across the globe.

How can I contact Q BioMed?

Q BioMed's mailing address is 366 MADISON AVENUE 3RD FLOOR, NEW YORK NY, 10017. The official website for Q BioMed is www.qbiomed.com. The company can be reached via phone at (646) 889-2226.

This page (OTCMKTS:QBIO) was last updated on 7/5/2022 by MarketBeat.com Staff

MarketBeat Resources

Premium Research Tools

MarketBeat All Access subscribers can access stock screeners, the Idea Engine, data export tools, research reports, and other premium tools.

Discover All Access

Market Data and Calendars

Looking for new stock ideas? Want to see which stocks are moving? View our full suite of financial calendars and market data tables, all for free.

View Market Data

Investing Education and Resources

Receive a free world-class investing education from MarketBeat. Learn about financial terms, types of investments, trading strategies and more.

Financial Terms
Details Here
MarketBeat - Stock Market News and Research Tools logo

MarketBeat empowers individual investors to make better trading decisions by providing real-time financial data and objective market analysis. Whether you’re looking for analyst ratings, corporate buybacks, dividends, earnings, economic reports, financials, insider trades, IPOs, SEC filings or stock splits, MarketBeat has the objective information you need to analyze any stock. Learn more about MarketBeat.

MarketBeat is accredited by the Better Business Bureau MarketBeat is rated as Great on TrustPilot

© American Consumer News, LLC dba MarketBeat® 2010-2022. All rights reserved.
326 E 8th St #105, Sioux Falls, SD 57103 | U.S. Based Support Team at contact@marketbeat.com | (844) 978-6257
MarketBeat does not provide personalized financial advice and does not issue recommendations or offers to buy stock or sell any security.

Our Accessibility Statement | Terms of Service | Do Not Sell My Information | RSS Feeds

© 2022 Market data provided is at least 10-minutes delayed and hosted by Barchart Solutions. Information is provided 'as-is' and solely for informational purposes, not for trading purposes or advice, and is delayed. To see all exchange delays and terms of use please see disclaimer.